NASDAQ$EVLO
Evelo Biosciences Inc · Q4 2021 earnings
Q4 2021 earnings · · Investor relations
Briefing
Evelo Biosciences reported financial results for Q4 2021 and business highlights.
Evelo Biosciences reported a net loss of $28.7 million for the fourth quarter of 2021, with R&D expenses at $18.9 million and G&A expenses at $8.7 million. Cash and cash equivalents were $68.4 million as of December 31, 2021.
- Oral presentation on EDP1815 Phase 2 data in psoriasis accepted in late-breaking abstract session at AAD on Saturday, March 26, 2022.
- Positive data reported on faster release capsule.
- Phase 2 data from EDP1815 in atopic dermatitis on-track for 1H 2023 readout.
- Statistically significant reductions in the Psoriasis Area and Severity Index (PASI) score were observed in two of the three cohorts treated with EDP1815
Headline financials
Revenue & EPS history
Evelo · Revenue · Quarterly
$0
Forward guidance
Evelo intends to move towards registration trials in psoriasis following the completion of meetings with health authorities this year. Topline data from 16-weeks of dosing in the Phase 2 trial in atopic dermatitis is anticipated in 1H 2023. Interim data from Phase 1b trial for EDP1867 is expected in early 2Q 2022. Initiation of clinical development of first extracellular vesicle (EV) anticipated in 3Q 2022. Phase 2 data from a cohort of patients with psoriasis expected in 2H 2023
Tailwinds
- Move towards registration trials in psoriasis following the completion of meetings with health authorities this year
- Topline data from 16-weeks of dosing in the Phase 2 trial in atopic dermatitis is anticipated in 1H 2023
- Interim data from Phase 1b trial for EDP1867 is expected in early 2Q 2022
- Initiation of clinical development of first extracellular vesicle (EV) anticipated in 3Q 2022
- Phase 2 data from a cohort of patients with psoriasis expected in 2H 2023
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2021
+1.3%
Avg return
Earnings day
-1.4%
Avg return
5 days after
-9.7%
Avg return
30 days after
54%
13 / 24 earnings
Positive
+32.3%
Q2 2023
Best reaction
-20.3%
Q1 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2023 | +0.0% | +0.0% | -9.8% | |
| Q3 2023 | -7.6% | +4.5% | +3.8% | |
| Q2 2023 | +32.3% | -30.5% | -41.0% | |
| Q1 2023 | +2.9% | +10.2% | -28.8% | |
| Q4 2022 | -17.8% | -27.0% | -46.9% | |
| Q3 2022 | +3.3% | -3.3% | -8.5% | |
| Q2 2022 | -7.1% | -10.5% | -25.4% | |
| Q1 2022 | -20.3% | -14.5% | -2.4% | |
| Q4 2021 | +29.4% | +13.5% | -26.3% | |
| Q3 2021 | +10.2% | +27.0% | +6.0% | |
| Q2 2021 | -0.9% | +5.0% | +20.7% | |
| Q1 2021 | +8.8% | -14.4% | +11.0% | |
| Q4 2020 | +14.5% | +21.2% | +1.6% | |
| Q3 2020 | -12.9% | -5.9% | +14.0% | |
| Q2 2020 | -1.6% | -0.5% | +15.2% | |
| Q1 2020 | -5.7% | -14.0% | -20.9% | |
| Q4 2019 | +1.8% | +12.2% | -28.4% | |
| Q3 2019 | -3.3% | -6.1% | -35.9% | |
| Q2 2019 | +3.9% | -2.2% | +7.0% | |
| Q1 2019 | +0.8% | -1.5% | -11.8% | |
| Q4 2018 | +1.3% | +3.0% | -6.9% | |
| Q3 2018 | +0.2% | +3.4% | +3.7% | |
| Q2 2018 | -3.4% | -5.9% | +2.6% | |
| Q1 2018 | +1.8% | +2.2% | -24.8% | |
| Q4 2017 | — | — | — | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro